Pathological overexpression of these inhibitors could reduce MMP-2 proteolytic activity below normal physiological levels, thus causing MMP-2 insufficiency as observed in liver cirrhosis and pancreatitis patients with high TIMP-2 levels23. This evidence concerns the gene MMP2 and cirrhosis of liver.